drugset / Trial / NCT04699838
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
Timeline
- Start
- 2021-04-20
- Primary completion
- 2026-07
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Background | Ceralasertib | Small molecule | 240 mg | Oral |
| Background | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Background | Etoposide | Small molecule | — | — |